Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBIT: 2014-2025

Historic EBIT for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$55.6 million.

  • ImmunityBio's EBIT rose 30.68% to -$55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$260.7 million, marking a year-over-year increase of 27.61%. This contributed to the annual value of -$344.2 million for FY2024, which is 4.99% up from last year.
  • As of Q3 2025, ImmunityBio's EBIT stood at -$55.6 million, which was up 21.96% from -$71.3 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's EBIT peaked at -$55.6 million during Q3 2025, and registered a low of -$111.6 million during Q1 2023.
  • In the last 3 years, ImmunityBio's EBIT had a median value of -$80.3 million in 2024 and averaged -$81.6 million.
  • Per our database at Business Quant, ImmunityBio's EBIT crashed by 156.67% in 2021 and then soared by 32.32% in 2025.
  • ImmunityBio's EBIT (Quarterly) stood at -$79.3 million in 2021, then declined by 7.10% to -$84.9 million in 2022, then fell by 0.58% to -$85.4 million in 2023, then rose by 18.72% to -$69.4 million in 2024, then spiked by 30.68% to -$55.6 million in 2025.
  • Its EBIT was -$55.6 million in Q3 2025, compared to -$71.3 million in Q2 2025 and -$64.4 million in Q1 2025.